期刊文献+

Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients 被引量:7

Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients
下载PDF
导出
摘要 Hepatocellular carcinoma (HCC) is the most common primary neoplasm of the liver and is one of the leading causes of cancer-related death worldwide. Liver transplantation (LT) has become one of the best curative therapeutic options for patients with HCC, although tumor recurrence after LT is a major and unaddressed cause of mortality. Furthermore, the factors that are associated with recurrence are not fully understood, and most previous studies have focused on the biological properties of HCC, such as the number and size of the HCC nodules, the degree of differentiation, the presence of hepatic vascular invasion, elevated serum levels of alpha-fetoprotein, and the tumor stage outside of the Milan criteria. Thus, little attention has been given to factors that are not directly related to HCC (i.e., “non-oncological factors”), which have emerged as predictors of tumor recurrence. This review was performed to assess the effects of non-oncological factors on tumor recurrence after LT. The identification of these factors may provide new research directions and clinical strategies for the prophylaxis and surveillance of tumor recurrence after LT, which can help reduce recurrence and improve patient survival. Hepatocellular carcinoma(HCC) is the most common primary neoplasm of the liver and is one of the leading causes of cancer-related death worldwide. Liver transplantation(LT) has become one of the best curative therapeutic options for patients with HCC, although tumor recurrence after LT is a major and unaddressed cause of mortality. Furthermore, the factors that are associated with recurrence are not fully understood, and most previous studies have focused on the biological properties of HCC, such as the number and size of the HCC nodules, the degree of differentiation, the presence of hepatic vascular invasion, elevated serum levels of alpha-fetoprotein, and the tumor stage outside of the Milan criteria. Thus, little attention has been given to factors that are not directly related to HCC(i.e., "non-oncological factors"), which have emerged as predictors of tumor recurrence. This review was performed to assess the effects of nononcological factors on tumor recurrence after LT. The identification of these factors may provide new research directions and clinical strategies for the prophylaxis and surveillance of tumor recurrence after LT, which can help reduce recurrence and improve patient survival.
出处 《World Journal of Gastroenterology》 SCIE CAS 2016年第9期2749-2759,共11页 世界胃肠病学杂志(英文版)
基金 Supported by National High-Tech R and D Program(863 Program,No.2012AA021003) the Tianjin Municipal Health Bureau Key Project,No.13KG103
关键词 Liver transplantation Immunosuppressive agents Hepatocellular carcinoma RECURRENCE Living donor Deceased donor Liver transplantation Immunosuppressive agents Hepatocellular carcinoma Recurrence Living donor Dece
  • 相关文献

参考文献112

  • 1Vivek Kohli,Ashish Singhal,Lenzi Elliott,Sajid Jalil.??Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation(J)Transplant International . 2012 (2)
  • 2Pratima Sharma,Kathy Welch,Hero Hussain,Shawn J. Pelletier,Robert J. Fontana,Jorge Marrero,Robert M. Merion.??Incidence and Risk Factors of Hepatocellular Carcinoma Recurrence After Liver Transplantation in the MELD Era(J)Digestive Diseases and Sciences . 2012 (3)
  • 3S. Miyagi,N. Kawagishi,S. Sekiguchi,Y. Akamatsu,K. Sato,I. Takeda,Y. Kobayashi,K. Tokodai,K. Fujimori,S. Satomi.??The Relationship Between Recurrences and Immunosuppression on Living Donor Liver Transplantation for Hepatocellular Carcinoma(J)Transplantation Proceedings . 2012 (3)
  • 4Sang‐Jae Park,Chris E. Freise,Ryutaro Hirose,Robert K. Kerlan,Francis Y. Yao,John P. Roberts,Parsia A. Vagefi.??Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma(J)Clin Transplant . 2012 (4)
  • 5T. Piardi,F. Gheza,B. Ellero,M. Woehl-Jaegle,D. Ntourakis,M. Cantu,E. Marzano,M. Audet,P. Wolf,Patrick Pessaux.??Number and Tumor Size Are Not Sufficient Criteria to Select Patients for Liver Transplantation for Hepatocellular Carcinoma(J)Annals of Surgical Oncology . 2012 (6)
  • 6Sabarinathan Ramachandran,Jane M. Liaw,Jianluo Jia,Sean C. Glasgow,Wei Liu,Krista Csontos,G.A. Upadhya,T. Mohanakumar,William C. Chapman.??Ischemia–reperfusion injury in rat steatotic liver is dependent on NFκB P65 activation(J)Transplant Immunology . 2012 (4)
  • 7Austin G. Acheson,Matthew J. Brookes,Donat R. Spahn.Effects of Allogeneic Red Blood Cell Transfusions on Clinical Outcomes in Patients Undergoing Colorectal Cancer Surgery: A Systematic Review and Meta-Analysis[J].Annals of Surgery.2012(2)
  • 8Abby B. Siegel,Emerson A. Lim,Shuang Wang,William Brubaker,Rosa D. Rodriguez,Abhishek Goyal,Judith S. Jacobson,Dawn L. Hershman,Elizabeth C. Verna,Jonah Zaretsky,Karim Halazun,Lorna Dove,Robert S. Brown,Alfred I. Neugut,Tomoaki Kato,Helen Remotti,Yael J. Coppleson,Jean C. Emond.??Diabetes, Body Mass Index, and Outcomes in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation(J)Transplantation Journal . 2012 (5)
  • 9Robert C. Grant,Lakhbir Sandhu,Peter R. Dixon,Paul D. Greig,David R. Grant,Ian D. McGilvray.Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta‐analysis[J].Clin Transplant.2012(1)
  • 10Manuel Rodríguez-Perálvarez,Emmanuel Tsochatzis,María Carmen Naveas,Giulia Pieri,Carmen García-Caparrós,James O’Beirne,Antonio Poyato-González,Gustavo Ferrín-Sánchez,Jose Luis Montero-álvarez,David Patch,Douglas Thorburn,Javier Brice?o,Manuel De la Mata,Andrew Kenneth Burroughs.Reduced Exposure to Calcineurin Inhibitors Early After Liver Transplantation Prevents Recurrence of Hepatocellular Carcinoma[J].Journal of Hepatology.2013

二级参考文献219

  • 1Jiang, Li,Yan, Lu-Nan.Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation[J].World Journal of Gastroenterology,2010,16(20):2468-2475. 被引量:11
  • 2Li, Chuan,Wen, Tian-Fu,Yan, Lu-Nan,Li, Bo,Yang, Jia-Ying,Wang, Wen-Tao,Xu, Ming-Qing,Wei, Yong-Gang.Outcome of hepatocellular carcinoma treated by liver transplantation:comparison of living donor and deceased donor transplantation[J].Hepatobiliary & Pancreatic Diseases International,2010,9(4):366-369. 被引量:5
  • 3Lu-Nan Yan, Bo Li, Yong Zeng, Tian-Fu Wen, Ji-Chun Zhao, Wen-Tao Wang, Jia-Yin Yang, Ming-Qing Xu,Yu-Kui Ma, Zhe-Yu Chen, Jiang-Wen Liu and Hong Wu Liver Transplantation Division, Department of Surgery, West China Hospital, Sichuan University, Chengdu 610041 , China.Modified techniques for adult-to-adult living donor liver transplantation[J].Hepatobiliary & Pancreatic Diseases International,2006,5(2):173-179. 被引量:6
  • 4Dong Q,Chan HL,Liu Z,Chan DP,Zhang B,Chen Y,Kung HF,Sung JJ,He ML. A1762T/G1764A mutations of hepatitis B virus,associated with the increased risk of hepatocellular carcinoma,reduce basal core promoter activities. Biochem Biophys Res Commun 2008; 374: 773-776.
  • 5Kusakabe A,Tanaka Y,Inoue M,Kurbanov F,Tatematsu K, Nojiri S,Joh T,Tsugane S,Mizokami M. A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan. J Gastroenterol 2011; 46: 117-124.
  • 6Tanaka Y,Mukaide M,Orito E,Yuen MF,Ito K,Kurbanov F,Sugauchi F,Asahina Y,Izumi N,Kato M,Lai CL,Ueda R,Mizokami M. Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol 2006; 45: 646-653.
  • 7Xu L,Qian G,Tang L,Su J,Wang JS. Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi,China. J Hepatol 2010; 53: 671-676.
  • 8Fan W,Shi B,Wei H,Du G,Song S. Comparison of hepatitis B X gene mutation between patients with hepatocellular carcinoma and patients with chronic hepatitis B. Virus Genes 2011; 42: 162-170.
  • 9Chu CM,Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005; 43: 411-417.
  • 10Fang ZL,Sabin CA,Dong BQ,Wei SC,Chen QY,Fang KX, Yang JY,Huang J,Wang XY,Harrison TJ. Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study. J Gen Virol 2008; 89: 2882-2890.

共引文献136

同被引文献48

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部